Douglas R. Galasko

Douglas R. Galasko's AcademicInfluence.com Rankings

Douglas R. Galasko

Medical

#1799

World Rank

#2175

Historical Rank

Neurology

#162

World Rank

#231

Historical Rank

medical Degrees

Douglas R. Galasko

Philosophy

#5386

World Rank

#8164

Historical Rank

Logic

#2675

World Rank

#3698

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Douglas R. Galasko's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Douglas R. Galasko Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Douglas R. Galasko's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria (2007) (4004)
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. (2011) (3651)
Diagnosis and management of dementia with Lewy bodies (2005) (3346)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (2014) (2513)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. (1996) (2280)
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) (1996) (2138)
Revising the definition of Alzheimer's disease: a new lexicon (2010) (1793)
Vitamin E and donepezil for the treatment of mild cognitive impairment. (2005) (1712)
Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
Diagnosis and management of dementia with Lewy bodies (2017) (1606)
The Parkinson Progression Marker Initiative (PPMI) (2011) (1159)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins (2007) (1037)
Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors (2008) (1033)
The Lewy body variant of Alzheimer's disease (1990) (984)
Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. (2004) (917)
The ageing systemic milieu negatively regulates neurogenesis and cognitive function (2011) (753)
The aging systemic milieu negatively regulates neurogenesis and cognitive function (2011) (745)
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis (2008) (701)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) (1993) (671)
Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease (1995) (632)
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. (2010) (575)
Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' (1998) (548)
Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide (1993) (511)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. (1998) (456)
Neuropsychological criteria for mild cognitive impairment improves diagnostic precision, biomarker associations, and progression rates. (2014) (418)
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease (2014) (400)
Clinical-neuropathological correlations in Alzheimer's disease and related dementias. (1994) (393)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease (2010) (393)
The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases (2007) (378)
Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? (2003) (359)
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease (2020) (356)
DLB and PDD boundary issues (2007) (351)
Consensus classification of posterior cortical atrophy (2017) (350)
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. (1997) (346)
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. (2012) (328)
Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy (2010) (326)
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression (2011) (320)
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis (2012) (308)
The Mini-Mental State Examination in the early diagnosis of Alzheimer's disease. (1990) (305)
Cognitive decline is faster in Lewy body variant than in Alzheimer's disease (1998) (283)
APOE ε4 increases risk for dementia in pure synucleinopathies. (2013) (282)
Distinctive patterns of DNA methylation associated with Parkinson disease (2013) (278)
Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: a clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease. (1999) (270)
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease (2011) (263)
Biological markers for therapeutic trials in Alzheimer’s disease Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease (2003) (261)
Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. (1995) (245)
Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile (2016) (243)
Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults (1995) (243)
Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. (1999) (238)
The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant (1996) (232)
Research criteria for the diagnosis of prodromal dementia with Lewy bodies (2020) (232)
Performance on the dementia rating scale in Parkinson’s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer’s disease (2003) (225)
Incidence of and risk factors for hallucinations and delusions in patients with probable AD (2000) (216)
The Role of Biomarkers in Clinical Trials for Alzheimer Disease (2006) (216)
Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. (2000) (212)
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. (2012) (208)
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). (1995) (205)
Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group (2021) (204)
Phosphorylated α-Synuclein in Parkinson’s Disease (2012) (203)
Progressive accumulation of amyloid‐β oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins (2010) (196)
Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC (2018) (196)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2019) (194)
Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD (2002) (189)
Biomarkers of oxidative damage and inflammation in Alzheimer's disease. (2010) (185)
Degree of bilingualism predicts age of diagnosis of Alzheimer's disease in low-education but not in highly educated Hispanics (2011) (182)
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease (2009) (179)
Rate of progression differs in frontotemporal dementia and Alzheimer disease (2005) (176)
Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. (2003) (175)
The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. (2010) (173)
Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease (2011) (172)
CSF Aβ42 and tau in Parkinson's disease with cognitive impairment (2010) (172)
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease (2010) (171)
Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study (2000) (170)
Neuropsychological Deficits Associated with Diffuse Lewy Body Disease (1996) (170)
Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype (2018) (169)
CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study (2016) (169)
Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementia. (2001) (169)
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease (2009) (169)
Pathological TDP-43 in parkinsonism–dementia complex and amyotrophic lateral sclerosis of Guam (2007) (167)
NPTX2 and cognitive dysfunction in Alzheimer’s Disease (2017) (165)
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. (2010) (164)
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study (2018) (163)
Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (2001) (161)
Effects of chronic stress on memory decline in cognitively normal and mildly impaired older adults. (2009) (161)
Altered expression of the synuclein family mRNA in Lewy body and Alzheimer’s disease (2001) (159)
Clinical and Neuropathological Findings in Lewy Body Dementias (1996) (155)
Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set (2018) (154)
Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies (2003) (154)
The apolipoprotein E allele epsi;4 is overrepresented in patients with the Lewy body variant of Alzheimer's disease (1994) (153)
SUBJECTIVE COGNITIVE COMPLAINTS CONTRIBUTE TO MISDIAGNOSIS OF MILD COGNITIVE IMPAIRMENT (2014) (153)
Preclinical cognitive markers of dementia of the Alzheimer type. (1994) (151)
Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease. (2007) (148)
Diagnosis and evaluation of dementia* (1995) (148)
Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease (1997) (148)
Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies (1993) (147)
Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. (1998) (145)
Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease (2005) (143)
Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease (2014) (142)
ADCS Prevention Instrument Project: Assessment of Instrumental Activities of Daily Living for Community-dwelling Elderly Individuals in Dementia Prevention Clinical Trials (2006) (141)
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. (2014) (140)
α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies (2018) (140)
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology (2012) (135)
PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease (2011) (134)
Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor and Cognitive Function in Non-Demented Subjects (2009) (132)
Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease (2018) (132)
Lewy body disease. (1992) (132)
SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease (2010) (128)
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. (2006) (126)
Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia (2005) (125)
Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype (2002) (124)
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer's Disease. (2015) (122)
CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease (2016) (120)
Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. (1993) (120)
Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease (2006) (119)
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions (2014) (119)
Safety, Tolerability, Pharmacokinetics, and Aβ Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals (2007) (119)
Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease. (1998) (118)
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort (2018) (113)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
Incidence of new-onset seizures in mild to moderate Alzheimer disease. (2012) (112)
Longitudinal stability of CSF tau levels in Alzheimer patients (1999) (111)
Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. (2009) (109)
Clinical and neuropsychological differences between patients with earlier and later onset of Alzheimer's disease (1996) (109)
Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year. (2013) (109)
The Alzheimer ’ s Disease Centers ’ Uniform Data Set ( UDS ) : The Neuropsychological Test Battery (2009) (107)
RESEARCH ARTICLE: Empiric Refinement of the Pathologic Assessment of Lewy‐Related Pathology in the Dementia Patient (2008) (107)
Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers (2019) (103)
The Effects of Prolonged Stress and APOE Genotype on Memory and Cortisol in Older Adults (2007) (101)
Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. (2014) (100)
Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study (2011) (100)
Lack of β-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC (2005) (100)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture (2021) (99)
miR-212 and miR-132 Are Downregulated in Neurally Derived Plasma Exosomes of Alzheimer’s Patients (2019) (99)
Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease (2010) (96)
Phosphorylated alpha-Synuclein in Parkinson's Disease (2012) (96)
Measuring cognitive change in a cohort of patients with Alzheimer's disease. (2000) (95)
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. (2011) (94)
Alzheimer's disease: The right drug, the right time (2018) (94)
The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease (1995) (91)
Human Apolipoprotein E Isoform‐Specific Differences in Neuronal Sprouting in Organotypic Hippocampal Culture (1999) (90)
Effect of TTP488 in patients with mild to moderate Alzheimer’s disease (2014) (90)
Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria. (2008) (90)
Global clinical dementia rating of 0.5 in MCI masks variability related to level of function (2011) (89)
Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults (2013) (89)
Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. (2007) (89)
Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. (2008) (88)
Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. (1997) (88)
Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults. (2015) (88)
Functional evaluation distinguishes MCI patients from healthy elderly people — The ADCS/MCI/ADL scale (2010) (87)
Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease (2016) (86)
Circadian alterations during early stages of Alzheimer's disease are associated with aberrant cycles of DNA methylation in BMAL1 (2017) (86)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls (2017) (85)
The Influence of Chronic Stress on Dementia-related Diagnostic Change in Older Adults (2012) (82)
Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam (2007) (82)
Repeated exposure to the Mini‐Mental State Examination and the Information‐Memory‐Concentration Test results in a practice effect in Alzheimer's disease (1993) (80)
Subjective Cognitive Decline Correlates With Depression Symptoms and Not With Concurrent Objective Cognition in a Clinic-Based Sample of Older Adults (2018) (80)
Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease (2015) (80)
ALS and PDC of Guam: Forty-year follow-up (2002) (79)
Biomarkers for Alzheimer's disease--clinical needs and application. (2006) (78)
Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid. (2009) (78)
A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease (2004) (77)
Neurological findings in Alzheimer's disease and normal aging. (1990) (77)
STIMULATED PLATELETS RELEASE AMYLOID β–PROTEIN PRECURSOR (1990) (76)
Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology (2017) (76)
Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. (2003) (76)
Longitudinal Analyses of Cerebrospinal Fluid α-Synuclein in Prodromal and Early Parkinson’s Disease (2019) (76)
Defective neuronal sprouting by human apolipoprotein E4 is a gain‐of‐negative function (2002) (75)
TAU as a susceptibility gene for amyotropic lateral sclerosis-parkinsonism dementia complex of Guam. (2001) (75)
Clinical Features Distinguishing Large Cohorts with Possible AD, Probable AD, and Mixed Dementia (1993) (75)
Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease (2018) (74)
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression (2020) (73)
Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimer’s Disease as Identified by Biomarkers (2011) (71)
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study (2020) (71)
4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration (2019) (70)
Prevalence of dementia in Chamorros on Guam (2007) (70)
Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies. (2008) (69)
Pupillary responses as a biomarker of early risk for Alzheimer’s disease: Association with tau not beta‐amyloid (2021) (69)
Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? (1996) (67)
Widespread microRNA dysregulation in multiple system atrophy – disease‐related alteration in miR‐96 (2014) (67)
Neuropsychological assessment of severely demeted elderly: the severe cognitive impairment profile. (1996) (67)
Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. (2008) (66)
Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997–2000 (2002) (66)
Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies (2019) (66)
Early versus late MCI: Improved MCI staging using a neuropsychological approach (2019) (65)
ADCS Prevention Instrument Project: Overview and Initial Results (2006) (64)
Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing (2018) (63)
Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease (2019) (62)
Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. (2007) (62)
An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behaviour (1998) (61)
Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation* (2015) (60)
Age at onset is associated with disease severity in Lewy body variant and Alzheimer's disease (2002) (60)
Age-dependent instability of mature neuronal fate in induced neurons from Alzheimer’s patients (2021) (60)
Galantamine Maintains Ability to Perform Activities of Daily Living in Patients with Alzheimer's Disease (2004) (60)
"Missed" Mild Cognitive Impairment: High False-Negative Error Rate Based on Conventional Diagnostic Criteria. (2016) (58)
Arguing against the proposed definition changes of PD (2016) (58)
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems (2013) (56)
A cerebrospinal fluid microRNA signature as biomarker for glioblastoma. (2017) (56)
Intracranial mass lesions associated with late-onset psychosis and depression. (1988) (54)
Analysis of extracellular RNA in cerebrospinal fluid (2017) (53)
Tau oligomers in cerebrospinal fluid in Alzheimer's disease (2017) (52)
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease (2011) (52)
Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome* (2011) (51)
A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium (2008) (50)
CD4+ T cells contribute to neurodegeneration in Lewy body dementia (2021) (50)
LACK OF CEREBRAL BMAA IN HUMAN CEREBRAL CORTEX (2009) (49)
Aβ1–42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD (2003) (49)
Phenotypic differences based on staging of Alzheimer's neuropathology in autopsy-confirmed dementia with Lewy bodies. (2016) (48)
Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease (2008) (46)
Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (46)
Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. (2009) (44)
A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations (2017) (42)
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders (2014) (42)
Early visuospatial deficits predict the occurrence of visual hallucinations in autopsy-confirmed dementia with Lewy bodies. (2012) (41)
Apolipoprotein-E ε-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease (1994) (41)
Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease (2000) (40)
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease (2017) (40)
Increasing Inaccuracy of Self-Reported Subjective Cognitive Complaints Over 24 Months in Empirically Derived Subtypes of Mild Cognitive Impairment (2018) (40)
Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span. (2014) (39)
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
Primary brain calcification: an international study reporting novel variants and associated phenotypes (2018) (39)
Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. (2012) (39)
Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross‐Sectional Study (2020) (38)
Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans (1998) (37)
Lewy Body Disorders. (2017) (36)
Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing (2018) (36)
A cerebrospinal fluid microRNA signature as biomarker for glioblastoma (2017) (36)
Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. (2009) (36)
Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease (2020) (36)
Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults (2017) (35)
Dementia with Lewy Bodies: Neuropsychological aspects of Lewy body dementia (1996) (35)
Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study (2017) (35)
The new Qualitative Scoring MMSE Pentagon Test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease. (2014) (34)
Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. (2019) (34)
Lack of beta-methylamino-l-alanine in brain from controls, AD, or Chamorros with PDC. (2005) (34)
Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease (2015) (34)
Sex differences in Alzheimer’s-related Tau biomarkers and a mediating effect of testosterone (2020) (34)
Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease. (2015) (33)
ADAM10 expression and promoter haplotype in Alzheimer's disease (2012) (32)
Subjective Cognitive Decline, Objective Cognition, and Depression in Older Hispanics Screened for Memory Impairment. (2018) (32)
Reduced hypocretin (orexin) levels in dementia with Lewy bodies (2010) (32)
Intracellular Aβ is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines (2002) (31)
Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex (2006) (31)
Interrater reliability of the new criteria for behavioral variant frontotemporal dementia (2012) (31)
Genetic-Evidence That the Lewy Body Variant Is Indeed a Phenotypic Variant of Alzheimers-Disease (1995) (30)
Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies (2020) (30)
The Mutation Matters: CSF Profiles of GCase, Sphingolipids, α‐Synuclein in PDGBA (2021) (30)
Quantifying Drug‐Induced Changes in Parkinsonian Rigidity Using an Instrumental Measure of Activated Stiffness (1992) (29)
CSF‐Phospho‐tau (181P) as a Promising Marker for Discriminating Alzheimer's Disease from Dementia with Lewy Bodies (2002) (29)
MCI-to-normal reversion using neuropsychological criteria in the Alzheimer's Disease Neuroimaging Initiative (2019) (28)
A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment. (2018) (28)
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials (2015) (27)
Dedifferentiation and neuronal repression define familial Alzheimer’s disease (2019) (27)
Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder (2020) (27)
Correction to: Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC (2018) (27)
Targeted Discovery and Validation of Plasma Biomarkers of Parkinson’s Disease (2014) (27)
Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer’s disease (2020) (27)
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention (2021) (27)
Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease. (2014) (27)
The impact of apolipoprotein E4 on cause of death in Alzheimer's disease (1997) (27)
Abnormal P600 word repetition effect in elderly persons with preclinical Alzheimer’s disease (2013) (26)
Rate of cognitive change in Alzheimer's disease: Methodological approaches using random effects models (2001) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
New approaches to diagnose and treat Alzheimer's disease: a glimpse of the future. (2001) (25)
Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease (1998) (25)
Heritability and genetic variance of dementia with Lewy bodies (2018) (25)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (25)
Neuropathology of dementia with Lewy bodies in advanced age: A comparison with Alzheimer disease (2010) (25)
Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid β 1-42 in CSF for the Diagnosis of Alzheimer's Disease. (2017) (24)
C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. (2013) (24)
Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span (2013) (24)
Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease (2017) (23)
A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy (2020) (23)
Adjunctive Therapy in Patients with Alzheimer’s Disease (1995) (23)
Artificially low mild cognitive impairment to normal reversion rate in the Alzheimer's Disease Neuroimaging Initiative (2019) (23)
Neuropsychiatric features of frontal lobe dysfunction in autopsy-confirmed patients with lewy bodies and "pure" Alzheimer disease. (2013) (22)
Influence of lifestyle modifications on age-related free radical injury to brain. (2014) (22)
CSF Tau and Aβ42: Logical Biomarkers for Alzheimer’s Disease? (1998) (21)
Potential use of γ-secretase modulators in the treatment of Alzheimer disease. (2012) (21)
No Long-Term Effect of Behavioral Treatment on Psychotropic Drug Use for Agitation in Alzheimer's Disease Patients (2002) (21)
Role of LRP in TGFβ2‐mediated neuronal uptake of Aβ and effects on memory (2004) (21)
Alzheimer disease: CSF biomarkers for Alzheimer disease — approaching consensus (2017) (21)
Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy. (2007) (21)
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials (2020) (21)
ApoE and CYP2D6 polymorphism with and without parkinsonism-dementia complex in the people of Chamorro, Guam (1996) (20)
Higher education is not associated with greater cortical thickness in brain areas related to literacy or intelligence in normal aging or mild cognitive impairment (2012) (20)
Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults (2020) (19)
A fibroblast growth factor binding protein in human cerebral spinal fluid (1995) (19)
Verbal learning and memory in patients with dementia with Lewy bodies or Parkinson's disease with dementia (2009) (19)
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression (2021) (19)
Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody. (2012) (19)
APOE DNA methylation is altered in Lewy body dementia (2018) (18)
High normal fasting blood glucose is associated with dementia in Chinese elderly (2010) (18)
Brain structure and cerebrovascular risk in cognitively impaired patients: Shanghai Community Brain Health Initiative-pilot phase. (2010) (17)
Visual search in Dementia with Lewy Bodies and Alzheimer's disease (2015) (17)
Effect of extrapyramidal signs and Lewy bodies on survival in patients with Alzheimer disease. (2002) (17)
Microstructural brain changes track cognitive decline in mild cognitive impairment (2018) (17)
The Diagnostic Evaluation of a Patient With Dementia (2013) (17)
Associations between CSF cortisol and CSF norepinephrine in cognitively normal controls and patients with amnestic MCI and AD dementia (2018) (17)
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease (2012) (16)
Multicenter Evaluation of New Instruments for Alzheimer's Disease Clinical Trials: Summary of Results (1997) (16)
Picking away at frontotemporal dementia. (2002) (16)
A comprehensive screening of copy number variability in dementia with Lewy bodies (2019) (16)
Insulin and Alzheimer’s disease (2003) (16)
Lewy bodies and dementia (2001) (16)
Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer’s Disease (2013) (15)
Improved Statistical Power of Alzheimer Clinical Trials by Item-Response Theory: Proof of Concept by Application to the Activities of Daily Living Scale (2013) (15)
Cerebrospinal fluid opens a window on Alzheimer disease. (1999) (14)
The spectrum of diseases with diffuse Lewy bodies. (1995) (14)
Amyloid-ß and Treatment Opportunities for Alzheimer's Disease (2000) (14)
Apolipoprotein-E epsilon-4 is associated with increased neurofibrillary pathology in the Lewy body variant of Alzheimer's disease. (1994) (13)
Sex Influences the Accuracy of Subjective Memory Complaint Reporting in Older Adults. (2018) (13)
Extrapyramidal signs and cognitive abilities in Alzheimer's disease (2001) (13)
Welcome to Alzheimer's Research & Therapy (2009) (13)
Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures (2019) (13)
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies (2017) (13)
THE ALS/PDC SYNDROME OF GUAM AND THE CYCAD HYPOTHESIS (2009) (12)
Visual Perceptual Organization Ability in Autopsy-Verified Dementia with Lewy Bodies and Alzheimer’s Disease (2016) (12)
Associations Between Microstructure, Amyloid, and Cognition in Amnestic Mild Cognitive Impairment and Dementia. (2019) (12)
Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Aβ42 and Tau. (2015) (12)
Expanding the Repertoire of Biomarkers for Alzheimer’s Disease: Targeted and Non-targeted Approaches (2015) (12)
Biological markers and the treatment of Alzheimer’s Disease (2001) (12)
LRP10 in α-synucleinopathies (2018) (12)
Motion discrimination in dementia with Lewy bodies and Alzheimer disease (2015) (12)
Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement? (2003) (12)
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). (2019) (12)
Proposed research criteria for prodromal behavioural variant frontotemporal dementia (2022) (11)
Comparison of the Memory Performance Index With Standard Neuropsychological Measures of Cognition (2011) (11)
Neuromotor abnormalities and risk for psychosis in Alzheimer’s disease (2003) (11)
Sensitivity of Diagnostic Criteria in Autopsy-Confirmed Patients with Behavioral Variant Frontotemporal Dementia (bvFTD): First Report of the International bvFTD Criteria Consortium (FTDC) (2011) (11)
Ataxic hemiparesis with intact sensory modalities. (1986) (11)
Trajectories of cognitive decline differ in hippocampal sclerosis and Alzheimer's disease (2019) (11)
Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease (2015) (11)
Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCI (2021) (10)
Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. (2019) (10)
Potential implications of practice effects in Alzheimer's disease prevention trials (2017) (10)
Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer’s Disease Pathology1 (2021) (10)
Reference data based insights expand understanding of human metabolomes (2020) (10)
A PROOF OF CONCEPT PHASE II STUDY REPURPOSING ATOMOXETINE FOR NEUROPROTECTION IN MILD COGNITIVE IMPAIRMENT: EVIDENCE FOR TARGET ENGAGEMENT, REGULATION OF CSF BIOMARKERS, AND DISEASE-MODIFYING POTENTIAL (2019) (9)
Stimulated platelets release amyloid beta-protein precursor. (1990) (9)
Longitudinal Changes in Cognition (1994) (9)
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans (2015) (9)
Age-at-Onset and APOE-Related Heterogeneity in Pathologically Confirmed Sporadic Alzheimer Disease (2021) (9)
Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines (2021) (8)
2-12-22 Utility of the CASI and IQCODE as screening instruments for dementia in natives of Guam (1997) (8)
Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia (2021) (8)
Distinct structural correlates of the dominant and nondominant languages in bilinguals with Alzheimer's disease (AD) (2019) (8)
Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings (2019) (8)
CSF tau and Abeta42: logical biomarkers for Alzheimer's disease? (1998) (8)
Clinical and Economic Characteristics of Milestones along the Continuum of Alzheimer's Disease: Transforming Functional Scores into Levels of Dependence. (2015) (8)
TDP‐43 Pathology Exacerbates Cognitive Decline in Primary Age‐Related Tauopathy (2022) (8)
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease (2022) (7)
A CLINICAL APPROACH TO DEMENTIA WITH LEWY BODIES (1999) (7)
Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment (2022) (7)
Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study (2020) (7)
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects (2014) (7)
Clinical-Neuropathological Correlations of Alzheimer's Disease and Related Dementias in Latino Volunteers. (2018) (7)
Prostaglandin E2 induced polymerization of human alpha-1-antichymotrypsin and suppressed its protease inhibitory activity: implications for Alzheimer's disease. (1998) (7)
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture (2020) (7)
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. (2020) (7)
Primary care screening for dementia and mild cognitive impairment. (2008) (7)
Association of Neurofibrillary Tangle Distribution With Age at Onset–Related Clinical Heterogeneity in Alzheimer Disease (2021) (7)
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium (2021) (7)
Dementia with Lewy Bodies: The nosological status of Lewy body dementia (1996) (6)
Lobar atrophy with dense-core (brain stem type) Lewy bodies in a patient with dementia (2004) (6)
Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease (2022) (6)
Knowledge of APOE genotype affects subjective and objective memory performance in healthy older adults (2012) (6)
Effects of time and cholinesterase inhibitor treatment on multiple cerebrospinal fluid parameters in Alzheimer's disease. (1999) (6)
Biomarkers in non-Alzheimer dementias (2004) (6)
Increased post-mitotic senescence in aged human neurons is a pathological feature of Alzheimer's disease. (2022) (6)
Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group (2016) (6)
Can Clinical Features Predict Tau Pathology in Patients with Behavioral Variant Frontotemporal Dementia (bvFTD)? (P05.101) (2013) (6)
Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease. (1998) (6)
Fractional synthesis and clearance rates for amyloid β (2011) (6)
An Item Pool to Assess Activities of Daily Living in Alzheimer’s Disease (1997) (6)
A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment (2021) (5)
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders (2022) (5)
P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study (2008) (5)
Temporal Sequence Learning in Healthy Aging and Amnestic Mild Cognitive Impairment (2013) (5)
Differential Effects of APOE Genotype on MicroRNA Cargo of Cerebrospinal Fluid Extracellular Vesicles in Females With Alzheimer’s Disease Compared to Males (2022) (5)
Anterior Cingulate Structure and Perfusion Is Associated with Cerebrospinal Fluid Tau Among Cognitively Normal Older Adult APOEɛ4 Carriers. (2019) (5)
Cross-Sectional and Longitudinal Validation of Serum Neurofilament Light Chain (NfL) as a Biomarker of Parkinson’s Disease Progression (2019) (4)
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 (2022) (4)
Clinical features and changing patterns of neurodegenerative disorders on Guam, 1997-2000. Authors' reply (2002) (4)
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
The effect of simvastatin on cerebrospinal fluid levels of apolipoprotein E in patients with alzheimer's disease (1995) (4)
Performance of Validated MicroRNA Biomarkers for Alzheimer's Disease in Mild Cognitive Impairment. (2020) (4)
Current Issues in Lewy Body Dementia Diagnosis, Treatment and Research (2012) (4)
ASLPrep: a platform for processing of arterial spin labeled MRI and quantification of regional brain perfusion (2022) (4)
3 Interpreting Cerebrospinal fluid tau levels in Alzheimer's disease (1996) (4)
The risk of developing Alzheimer's disease associated with the APOE promoter polymorphisms (1999) (4)
Failure to stop autocorrect errors in reading aloud increases in aging especially with a positive biomarker for Alzheimer's disease. (2020) (4)
Cholinergic deficits in the brains of patients with parkinsonism–dementia complex of Guam (2001) (4)
Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD (2020) (4)
Temporal order of clinical and biomarker changes in familial frontotemporal dementia (2022) (4)
Amyloid-beta and treatment opportunities for Alzheimer's disease. (2000) (4)
Community memory screening as a strategy for recruiting older adults into Alzheimer’s disease research (2020) (4)
Data-Driven vs Consensus Diagnosis of MCI (2021) (4)
DT-01-07 TREATMENT OF EARLYAD SUBJECTS WITH BAN2401, AN ANTI-Ab PROTOFIBRILMONOCLONALANTIBODY, SIGNIFICANTLY CLEARS AMYLOID PLAQUE AND REDUCES CLINICAL DECLINE (2018) (3)
Faculty Opinions recommendation of Individual variability in functional connectivity architecture of the human brain. (2013) (3)
Genetic risk factors for posterior cortical atrophy (2015) (3)
A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time? (2022) (3)
α‐Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α‐Synuclein in the Context of Co‐Pathology and Non‐LBD Diagnoses (2022) (3)
NEUROPSYCHOLOGICAL CRITERIA FOR MCI IMPROVES DIAGNOSTIC PRECISION, CSF BIOMARKER ASSOCIATIONS, AND PROGRESSION RATES (2014) (3)
Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry (2000) (3)
Long‐standing multiple system atrophy‐Parkinsonism with limbic and FTLD‐type α‐synuclein pathology (2021) (3)
Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease (2021) (3)
Arterial stiffening acts synergistically with APOE genotype and AD biomarker status to influence memory in older adults without dementia (2021) (3)
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease (2012) (3)
Dedifferentiation orchestrated through remodeling of the chromatin landscape defines PSEN1 mutation-induced Alzheimer’s Disease (2019) (3)
Right sizing funding for Alzheimer's disease (2011) (2)
Assessing quality of life by EQ-5D among Chinese elderly with cognitive function impairment: Findings from SCOBHI pilot (2009) (2)
Arterial stiffness acts synergistically with APOE genotype and amyloid status to predict cognitive impairment in non‐demented elderly (2020) (2)
Brain volumes in Guam dementia vs Parkinson dementia complex vs aging Chamorro adults (2007) (2)
Dynamics of neuroinflammation in Alzheimer's disease (2022) (2)
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. (2021) (2)
Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort (2022) (2)
Deep sncRNA-seq of the PPMI cohort to study Parkinson’s disease progression (2020) (2)
P3-089: Cerebrospinal fluid biomarkers distinguish mild Alzheimer's disease and mild cognitive impairment from cognitively healthy aging (2008) (2)
Gantenerumab in‐depth outcomes (2020) (2)
P3-344 Differential contributions of cognitive and behavioral deficits to functional impairment in FTD and AD (2004) (2)
Mechanisms Defining the Neuronal State Space (2018) (2)
Shanghai community brain health initiative pilot study: Neuropsychological results (2009) (2)
COMPOSITE ENDPOINTS FOR ALZHEIMER’S DISEASE CLINICAL TRIALS: IMPROVED PERFORMANCE VIA OPTIMAL WEIGHTING OF COMPONENT MEASURES (2018) (2)
Ttp488: From futile to fast track (2015) (2)
Determinants of survival in autopsy-confirmed patients with behavioral variant frontotemporal dementia (bvFTD): Second Report of the international bvFTD criteria consortium (FTDC) (2011) (1)
Clinical Features of Dementia with Lewy Bodies (2002) (1)
CERTAIN PLASMA N-TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND AD-MCI COMPARED TO CONTROLS (2018) (1)
The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer's disease spectrum (2022) (1)
THE ASSOCIATION BETWEEN INSTRUMENTAL ACTIVITIES OF DAILY LIVING AND CORTICAL AMYLOID IN COGNITIVELY NORMAL OLDER ADULTS SCREENING FOR THE A4 STUDY (2019) (1)
NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression (2021) (1)
Perception of fragmented letters differentiates pathologically confirmed dementia with Lewy bodies from Alzheimer’s disease (2020) (1)
Neuropathological validation of plasma GFAP (2022) (1)
Selective rubella vaccination programmes: a survey of districts in England and Wales. (1994) (1)
Pharmacological Approaches To Behavioral Symptoms In Alzheimer’s Disease (1996) (1)
Parkinson's disease causality and heterogeneity: a proteogenomic view (2022) (1)
Perception of stigma and willingness to participate in a cohort study among proxy respondents and controls in Shanghai, China: Scobhi-pilot (2009) (1)
Encouraging trends toward reduced risk of Alzheimer disease: What's good for the heart is good for the brain. (2015) (1)
Correction to: 4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration (2019) (1)
P.4.005 Functional improvement from treatment with the NMDA antagonist memantine: Results of a 28-week, randomized, placebo-controlled study in advanced Alzheimer's disease (2003) (1)
Dementia with Lewy Bodies: Résumé of treatment workshop sessions (1996) (1)
Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults (2017) (1)
Brain microstructure mediates effects of tau on cognitive decline in early Alzheimer’s disease (2021) (1)
CSF BIOMARKERS OF AMYLOID, TAU AND SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IN CSF AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD (2019) (1)
Leon Thal, MD (2007) (1)
Transcriptomic profiling of sporadic Alzheimer’s disease patients (2022) (1)
Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease (2012) (1)
A TOMM40 SNP in APOE-ε4 noncarriers increases risk for multiple types of dementia (2013) (1)
DEMENTIA WITH LEWY BODIES (2007) (1)
Ttp488 path to registration: Leveraging enrichment strategies (2015) (1)
Editorial Welcome to Alzheimer's Research & Therapy (2009) (1)
Solanezumab in‐depth outcomes (2020) (1)
Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? (2013) (1)
Title Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN 1 A 431 E-associated familial Alzheimer ' s disease Permalink (2010) (1)
O2-04-06: Randomized clinical trial of antioxidant treatment in Alzheimer's disease with CSF biomarker measures (2008) (1)
Shanghai community brain health initiative: Pilot study. Neuropsychological results (2009) (1)
Webinar | Unlocking the elusive mind: The role of protein biomarkers in understanding neurodegenerative disease (2017) (1)
Alzheimer's Disease Cooperative Study Prevention Instrument Project Assessing Resource Use and Volunteer and Paid Work in Healthy Elders: A Longitudinal Study (2014) (1)
CSF BIOMARKERS OF SYNAPTIC DAMAGE (NEUROGRANIN, SNAP25) AND INTERNEURON-DEPENDENT SYNAPTIC HOMEOSTASIS (NPTX2) IMPROVE DIAGNOSTIC CLASSIFICATION OF MCI AND AD AND CORRELATE WITH COGNITION (2019) (1)
PREDICTION OF CONVERSION OF MILD COGNITIVE IMPAIRMENT TO DEMENTIA WITH NEURONALLY DERIVED BLOOD EXOSOME PROTEIN PROFILE (2016) (1)
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting (2021) (1)
Assessment of Cognitive Complaints Toolkit for Alzheimer's Disease Instruction Manual (2018) (1)
Functional improvement from treatment with the NMDA antagonist memantine Results of a 28-week, randomized, placebo-controlled study in advanced Alzheimers disease (2003) (1)
A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future (2020) (1)
CSF-phospho-tau as a promising marker for discriminating Alzheimer disease from Lewy body dementia (2000) (1)
Progress in Alzheimer's disease research circa 2013: Is the glass half empty or half full? (2013) (1)
The memory disorders clinic. (2008) (1)
A Case of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FET) With Corticobasal Features and Language Deficits. (2021) (1)
Searching for Neurodegeneration in the Blood of Patients With Alzheimer Disease. (2017) (1)
CSF biomarkers as outcome measures in clinical trials (2009) (1)
TRAUMATIC BRAIN INJURY (TBI) AND DEMENTIA PROGRESSION (2016) (1)
Primary brain calcification: an international study reporting novel variants and associated phenotypes (2018) (1)
Advances in Research on Mild Cognitive Impairment (2012) (1)
Early Onset Familial Alzheimer's Disease: Is a Mutation Predictive of Pathology? (2005) (1)
Disease-a-month: Introduction (2000) (0)
Qualification of classical biomarkers for Alzheimer’s Disease in a multiplex format in blood using a new technology (2022) (0)
Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in PeopleWithout Cognitive Impairment FromAcross the Adult Life Span (2014) (0)
The role of apolipoprotein E testing in the diagnosis of Alzheimer's disease. (1998) (0)
Modulation of Aβ42 in vivo by γ-secretase modulator in primates and humans (2015) (0)
Plasma p‐tau231 in the Alzheimer’s disease continuum: A multi‐cohort evaluation of diagnostic performance, detection of Aβ pathology and preclinical application (2021) (0)
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials (2020) (0)
Regional North American Annual Meeting of the World Federation of Neurology – Research Group on Neuroepidemiology (2000) (0)
COGNITIVE STAGE AND BIOMARKER PROFILE PREDICTORS OF DEMENTIA: A DISCRETE-TIME SURVIVAL ANALYSIS (2019) (0)
Elevated Blood Pressure And Risk Of Incident Amnestic Mild Cognitive Impairment/Alzheimer’s Disease (S62.003) (2014) (0)
Cerebrospinal fluid and brain Î±-synuclein seed amplification in autopsy-confirmed Lewy body disease relates to the distribution of pathology (2022) (0)
Genetic variation within APP processing genes correlates with cerebrospinal fluid APP cleavage product levels in Alzheimer patients and cognitively normal subjects (2010) (0)
A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 (2010) (0)
Biological standards to control variability in cerebrospinal fluid beta-amyloid readings (2012) (0)
P3-085: Age- and APOE-related cerebrospinal fluid Alzheimer's disease biomarker changes in normal controls (2008) (0)
Objective subtle cognitive decline is associated with a more rapid increase in plasma phosphorylated‐tau181 levels over time (2021) (0)
Non‐demented elderly Latinos structurally and demographically matched to non‐Latino whites perform worse on visuo‐executive cognitive tests (2020) (0)
Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings (2019) (0)
Recent Alzheimer's disease research highlights (2012) (0)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) (0)
Reply from the Authors (1990) (0)
Author response: NPTX2 and cognitive dysfunction in Alzheimer’s Disease (2017) (0)
P3-090: Cerebrospinal fluid norepinephrine increases with aging, Alzheimers disease and APOE4 genotype (2008) (0)
DIFFERING LONGITUDINAL NEUROPSYCHOLOGICAL PROFILES AND TRAJECTORIES OF EMPIRICALLY DERIVED SUBTYPES OF MCI (2019) (0)
Tau oligomers in CSF: A novel biomarker for the diagnosis and evaluation of treatment for Alzheimer's disease and tauopathies (2013) (0)
O4-06-05 Differential prediction of global cognitive decline in autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease (2004) (0)
Word Generation from Letter and Semantic Categories Across the Alzheimer’s Disease Spectrum (2022) (0)
DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT AND LONGITUDINAL COGNITIVE DECLINE DIFFER IN PARKINSON’S DISEASE DEMENTIA (PDD), DEMENTIA WITH LEWY BODIES (DLB), AND ALZHEIMER’S DISEASE (AD) (2019) (0)
RAPID AND ULTRA-SENSITIVE DETECTION OF α-SYNUCLEIN SEEDS IN BRAIN AND CEREBROSPINAL FLUID BY α-SYN RT-QUIC: AN AID TO DIAGNOSIS FOR PD AND DLB (2018) (0)
Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders (2021) (0)
Prevalence study in Shanghai (2009) (0)
P2-216: Working memory deficits are greater in patients with autopsy-confirmed dementia with Lewy bodies (DLB) than in those with Alzheimer's disease (AD) (2008) (0)
Lewy Body Dementia (2008) (0)
DEVELOPMENT OF THE NON-DECLARATIVE MEMORY PRIMING DEFICIT OVER THE COURSE OF ALZHEIMER’S DISEASE (2017) (0)
PULSE PRESSURE IS ASSOCIATED WITH AD BIOMARKERS (2014) (0)
S1-02-05 Symposia session (2004) (0)
P4-279: Progressive accumulation of Abeta oligomers in the brains of patients with Alzheimer's disease is associated with selective alterations in synaptic proteins (2008) (0)
Galasko 326 THE WHAT AND WHERE OF DEMENTIA WITH LEWY BODIES PATHOLOGY (2017) (0)
NEURONAL PENTRAXIN 2 (NPTX2): A SYNAPTIC BIOMARKER OF COGNITIVE DYSFUNCTION IN ALZHEIMER’S DISEASE (2017) (0)
Accumulation of Abeta oligomers in Alzheimer's disease is associated with cognitive impairment by disrupting scaffold dendritic spine proteins: Effects of immunotherapy (2009) (0)
P3-088: Identification of potential biomarkers for Alzheimer's disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis and tandem mass spectrometry: A multi-institutional collaborative study (2008) (0)
In Reply (1992) (0)
Differential impact of APOE on associations between phosphorylated tau 181 and multi‐domain cognitive outcomes using cerebrospinal fluid and plasma markers (2022) (0)
Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease (2021) (0)
RISK FACTORS FOR CLINICAL AD IN U.S. LATINO POPULATIONS: AN ANALYSIS OF THE NACC DATABASE (2018) (0)
Prevalence study in Shanghai (2009) (0)
Part V. Genetic advances and biological markers for Alzheimer's disease. (2000) (0)
Incorporation of plasma biomarkers for screening and diagnosis in primary care (2022) (0)
Strategies of word production in AD, LBV, and elderly controls (1997) (0)
Faculty Opinions recommendation of A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. (2012) (0)
Evaluation of the relationship between TTP488 plasma concentrations and changes in ADAS-cog relative to placebo (2013) (0)
Shanghai community brain health initiative (scobhi) pilot study: methods and participation rates (2009) (0)
P1-003 ADCS Prevention instrument project: assessment of activities of daily living (ADL) (2004) (0)
Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies (2020) (0)
Sex differences in the association between plasma and CSF p‐tau (2021) (0)
Longitudinal change in CSF biomarkers, especially NPTX2, in non‐demented elderly predicts cognitive decline and conversion to dementia (2020) (0)
Contact Factors Differ for Dementia and Amnestic MCI in Chinese Elders: The Pilot SCOBHI Study. (2010) (0)
P-027 CSF transthyretin levels are associated with APOE genotype and CSF aβ42 in AD (2007) (0)
CSF and plasma biomarkers for DLB (2020) (0)
A TOMM40 SNP IN APOE E4 NON-CARRIERS INCREASES RISK FOR MULTIPLE TYPES OF DEMENTIA (2013) (0)
Clinical and Neuropsychological Features of Pure and Mixed Hippocampal Sclerosis Dementia (P05.039) (2012) (0)
Sensitivity of restriction spectrum imaging to memory and neuropathology in Alzheimer’s disease (2017) (0)
IN CSFAS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND AD (2019) (0)
NPTX2 LEVELS IN CSF AS POTENTIAL PREDICTOR OF COGNITIVE DYSFUNCTION IN THE AD CONTINUUM (2019) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
APP Processing Genes and Cerebrospinal Fluid APP Cleavage Product Levels in Alzheimer’s Disease (2011) (0)
Web‐based requisitioning, tracking and laboratory result reporting system for clinical trials using a central laboratory (2020) (0)
CSF BIOMARKERS RELATED TO NEURODEGENERATION AS PREDICTORS OF COGNITIVE PROGRESSION IN MCI AND ELDERLY CONTROLS (2019) (0)
Faculty Opinions recommendation of Tau-mediated nuclear depletion and cytoplasmic accumulation of SFPQ in Alzheimer's and Pick's disease. (2012) (0)
Faculty Opinions recommendation of An epigenetic blockade of cognitive functions in the neurodegenerating brain. (2012) (0)
Age, clinical indices and neuropathology in Alzheimer disease and dementia with lewy bodies (2010) (0)
APPROPRIATE USE CRITERIA FOR LUMBAR PUNCTURE AND CEREBROSPINAL FLUID TESTING IN THE DIAGNOSIS OF ALZHEIMER’S DISEASE (2018) (0)
Differences in the performance of “pure” alzheimer's disease and the lewy body variant on the mattis dementia rating scale (1996) (0)
Investigating the genetic architecture of Dementia with Lewy bodies: a genome-wide association study (2018) (0)
Decreased body mass index in the preclinical stage of autosomal dominant Alzheimer’s disease (2017) (0)
Selective tau seeding assays and isoform-specific antibodies define neuroanatomic distribution of progressive supranuclear palsy pathology arising in Alzheimer’s disease (2022) (0)
Age‐at‐Onset and APOE Related Heterogeneity in the Clinical, Plasma Biomarker, and Neuropathologic Presentation of Alzheimer’s Disease (AD) (2022) (0)
Defectiv eNeurona lSproutin gb yHuman Apolipoprotei nE 4I sa Gain-of-Negative Function (2002) (0)
Assessment of heterogeneity and disease onset in the Parkinson's Progression Markers Initiative (PPMI) cohort using the Î±-synuclein seed amplification assay: a cross-sectional study (2023) (0)
APOE differentially moderates cerebrospinal fluid and plasma phosphorylated tau181 associations with multi-domain cognition (2023) (0)
Higher blood glucose is associated with dementia among Chinese elderly independent of vascular risk factors and white matter hyperintensity volume: findings from SCOBHI (2009) (0)
Interaction Effects of Event-based Stress and APOE-e4 Genotype on Cortisol and Memory in Older, Nondemented Subjects (2006) (0)
Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol (2020) (0)
ASSOCIATION OF BRAIN MICROSTRUCTURE AND AMYLOID-β WITH COGNITIVE DECLINE IN EARLY ALZHEIMER’S DISEASE (2019) (0)
Reply from the Authors (1990) (0)
Exploring molecular biomarkers with potential prognostic value in longitudinal observational studies on Alzheimer’s disease (2020) (0)
Gantnerumab In-depth Outcomes (2020) (0)
P1-407 ADCS prevention instrument project: overview and initial results (2004) (0)
PL2-01 Biomarkers and early diagnosis of Alzheimer’s Disease (2007) (0)
1st Conference Clinical Trials on Alzheimer’s Disease September 17-18-19, 2008 School of Medecine Montpellier, France (2008) (0)
Bone Scintigraphy (1982) (0)
Robert Katzman honored. (2006) (0)
P3-064: Can SorLA/LR11, a sorting protein limiting Abeta production, serve as both therapeutic and diagnostic target in Alzheimer's disease? (2008) (0)
ANTICHOLINERGIC MEDICATION USE INTERACTS WITH APOE-ɛ4 GENOTYPE TO INCREASE RISK FOR INCIDENT MCI OVER A 10-YEAR PERIOD AMONG COGNITIVELY HEALTHY OLDER ADULTS: AN ALZHEIMER’S DISEASE NEUROIMAGING STUDY (2018) (0)
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease (2018) (0)
The relationship between plasma matrix metalloproteinase‐9 and cerebrospinal fluid biomarkers of tau is sex‐dependent (2022) (0)
Comparison of the Telephone‐Montreal Cognitive Assessment (T‐MoCA) and Telephone Interview for Cognitive Status (TICS) as Remote Screening Tests for Early Alzheimer’s Disease. (2022) (0)
Trajectory of Memory Decline Differs in Hippocampal Sclerosis and Alzheimer’s Disease (P5.192) (2018) (0)
Assessing rates of cognitive decline in Alzheimer's disease and dementia with Lewy bodies (2013) (0)
Shanghai community brain health initiative (scobhi) pilot study: apoe findings (2009) (0)
Guest authorship, mortality reporting, and integrity in rofecoxib studies. (2008) (0)
Elevated pulse pressure predicts longitudinal accumulation of tau PET in older adults without dementia (2020) (0)
Behavioral abnormalities are associated with milder dementia in Alzheimer's disease than in dementia with lewy bodies (2011) (0)
Identification of a sex-specific genetic signature in dementia with Lewy bodies: a meta-analysis of genome-wide association studies (2022) (0)
P1-133 Underdetection of memory impairment in elderly primary care patients with memory complaints (2004) (0)
Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems (2013) (0)
Cumulative cognitive deficits of Lewy body disease and Alzheimer’s disease neuropathology (2020) (0)
[ALS, Parkinson-Dementia complex and late-life dementia in the Chamorros Guam--an update]. (2007) (0)
Tau seeds are widespread in the brain at the earliest stages of Alzheimer’s disease–related changes (2021) (0)
Alzheimer ’ s disease : The right drug , the right time Lessons from failed clinical trials can improve the development of Alzheimer ’ s disease – modifying therapies (2018) (0)
Assessment of CSF levels of tau protein in patients with Alzheimer's disease and mild dementia (1997) (0)
Clinical value of CSF tau, p‐tau181, neurogranin and neurofilaments in familial frontotemporal lobar degeneration (2021) (0)
Autocorrection if→of function words in reading aloud: A novel marker of Alzheimer's risk. (2022) (0)
P1-276: Voxel-based correlations between cerebral glucose metabolism and cerebrospinal fluid Alzheimer's disease biomarkers in normal controls (2008) (0)
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood (2021) (0)
A mass spectrometry-based method to quantify in parallel Tau and amyloid β 1–42 in CSF for the diagnostic of Alzheimer’s Disease (2017) (0)
biomarkers DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and (2007) (0)
Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study (2010) (0)
P63 Informed consent issues when including genetic testing in clinical trials (1996) (0)
The complexity of DLB: U.S.‐based Dementia with Lewy Body Consortium (2020) (0)
Alzheimer’s disease and the processing of uncertainty during choice task performance: Executive dysfunction within the Hick–Hyman law (2019) (0)
Differences in MRI measures of brain volume, white matter hyperintensities and infarcts in Chinese: The Shanghai Community Brain Health Initiative (SCOBHI) (2009) (0)
Faculty Opinions recommendation of The age of olfactory bulb neurons in humans. (2012) (0)
Cholesterol metabolites as endogenous gamma-secretase modulators (2013) (0)
P-106 Gender, age, and APOE genotype effects on CSF Aβ42 in cognitively normal adults (2007) (0)
Dynamic measurement scale development for clinical trials in targeted populations (1998) (0)
VISUAL SENSORY BINDING IN PRECLINICAL AD (2019) (0)
Neuropsychiatric symptoms impact associations between plasma neurofilament light and cognition in individuals with Lewy body pathology, but not in Alzheimer’s disease. (2022) (0)
Human apolipoprotein E4 has a gain-of-negative-function in supporting mossy fiber axon sprouting in organotypic hippocampal slice culture (2000) (0)
Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson's disease (2023) (0)
P3-147 The prevalence of dementia among elderly chamorros on guam and lack of association with the APO e4 allele (2006) (0)
Visual Sensory Binding is Associated with CSF Neurogranin in Cognitively Healthy Older Adults (2022) (0)
DEMENTIA WITH LEWY BODIES CONSORTIUM: METHODOLOGY AND INITIAL SUBJECT CHARACTERISTICS (2018) (0)
THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOWARD OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE (2018) (0)
Antioxidants for Alzheimer disease-reply. (2013) (0)
IC-03-04: Voxel-based correlations between cerebral glucose metabolism and cerebrospinal fluid AD biomarkers in normal controls (2008) (0)
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration (2021) (0)
Genome-wide association analysis of Dementia with Lewy bodies reveals unique genetic architecture (2017) (0)
Biomarkers in predicting early in Alzheimer's disease (2000) (0)
Differences in MRI measures of brain volume, white matter hyperintensities and infarcts in Chinese: The Shanghai Community Brain Health Initiative (SCOBHI) (2009) (0)
Agents de reduction de a$g(b)42 (2001) (0)
Faculty Opinions recommendation of Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Douglas R. Galasko?

Douglas R. Galasko is affiliated with the following schools:

University of San Diego
University of California, San Diego

Douglas R. Galasko's Academic­Influence.com Rankings

Douglas R. Galasko's Degrees

Why Is Douglas R. Galasko Influential?

Douglas R. Galasko's Published Works

Published Works

What Schools Are Affiliated With Douglas R. Galasko?

Douglas R. Galasko's AcademicInfluence.com Rankings